Senseonics宣布与Beta Bionics达成战略合作，将Eversense® 365整合至Ilet®仿生胰腺系统

美股速递

4 hours ago

Senseonics Holdings, Inc.（以下简称“Senseonics”）今日正式宣布，已与Beta Bionics, Inc.达成一项战略合作伙伴关系。双方将携手推进连续血糖监测技术与智能胰岛素输送系统的深度融合，具体而言，Senseonics旗下创新产品Eversense® 365传感器将被整合进Beta Bionics研发的Ilet®仿生胰腺平台。

这一合作标志着糖尿病管理领域两大前沿技术力量的强强联合。Eversense® 365作为一款植入式连续血糖监测系统，以其长达一年的佩戴寿命和卓越的准确性著称；而Ilet®仿生胰腺则采用自动化胰岛素递送算法，能够根据实时血糖数据自主调节胰岛素输注，极大减轻患者的日常管理负担。

通过此次整合，双方旨在为糖尿病患者打造一个更加智能化、无缝衔接的闭环管理解决方案。Senseonics首席执行官在声明中表示，与Beta Bionics的合作将充分发挥各自技术优势，推动个性化糖尿病护理迈向新台阶。Beta Bionics方面亦强调，Eversense® 365的长期监测能力与Ilet®系统的自适应算法相结合，有望显著提升血糖控制效果，并改善患者的生活质量。

据悉，双方团队已启动技术对接与临床验证工作，后续将陆续公布更多合作细节及产品上市时间表。业内分析人士认为，此次跨界合作不仅巩固了两家公司在糖尿病科技领域的市场地位，也可能为未来更广泛的集成生态系统奠定基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1173059523"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1173059523\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1173059523?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-09-14 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173059523","market":"us","top_or_hot":-1,"title":"Senseonics宣布与Beta Bionics达成战略合作，将Eversense® 365整合至Ilet®仿生胰腺系统","media":"美股速递","content":"<p>Senseonics Holdings, Inc.（以下简称“Senseonics”）今日正式宣布，已与Beta Bionics, Inc.达成一项战略合作伙伴关系。双方将携手推进连续血糖监测技术与智能胰岛素输送系统的深度融合，具体而言，Senseonics旗下创新产品Eversense® 365传感器将被整合进Beta Bionics研发的Ilet®仿生胰腺平台。</p>\n<p>这一合作标志着糖尿病管理领域两大前沿技术力量的强强联合。Eversense® 365作为一款植入式连续血糖监测系统，以其长达一年的佩戴寿命和卓越的准确性著称；而Ilet®仿生胰腺则采用自动化胰岛素递送算法，能够根据实时血糖数据自主调节胰岛素输注，极大减轻患者的日常管理负担。</p>\n<p>通过此次整合，双方旨在为糖尿病患者打造一个更加智能化、无缝衔接的闭环管理解决方案。Senseonics首席执行官在声明中表示，与Beta Bionics的合作将充分发挥各自技术优势，推动个性化糖尿病护理迈向新台阶。Beta Bionics方面亦强调，Eversense® 365的长期监测能力与Ilet®系统的自适应算法相结合，有望显著提升血糖控制效果，并改善患者的生活质量。</p>\n<p>据悉，双方团队已启动技术对接与临床验证工作，后续将陆续公布更多合作细节及产品上市时间表。业内分析人士认为，此次跨界合作不仅巩固了两家公司在糖尿病科技领域的市场地位，也可能为未来更广泛的集成生态系统奠定基础。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Senseonics宣布与Beta Bionics达成战略合作，将Eversense® 365整合至Ilet®仿生胰腺系统</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSenseonics宣布与Beta Bionics达成战略合作，将Eversense® 365整合至Ilet®仿生胰腺系统\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1004306016\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">美股速递 </p>\n<p class=\"h-time\">2026-09-14 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Senseonics Holdings, Inc.（以下简称“Senseonics”）今日正式宣布，已与Beta Bionics, Inc.达成一项战略合作伙伴关系。双方将携手推进连续血糖监测技术与智能胰岛素输送系统的深度融合，具体而言，Senseonics旗下创新产品Eversense® 365传感器将被整合进Beta Bionics研发的Ilet®仿生胰腺平台。</p>\n<p>这一合作标志着糖尿病管理领域两大前沿技术力量的强强联合。Eversense® 365作为一款植入式连续血糖监测系统，以其长达一年的佩戴寿命和卓越的准确性著称；而Ilet®仿生胰腺则采用自动化胰岛素递送算法，能够根据实时血糖数据自主调节胰岛素输注，极大减轻患者的日常管理负担。</p>\n<p>通过此次整合，双方旨在为糖尿病患者打造一个更加智能化、无缝衔接的闭环管理解决方案。Senseonics首席执行官在声明中表示，与Beta Bionics的合作将充分发挥各自技术优势，推动个性化糖尿病护理迈向新台阶。Beta Bionics方面亦强调，Eversense® 365的长期监测能力与Ilet®系统的自适应算法相结合，有望显著提升血糖控制效果，并改善患者的生活质量。</p>\n<p>据悉，双方团队已启动技术对接与临床验证工作，后续将陆续公布更多合作细节及产品上市时间表。业内分析人士认为，此次跨界合作不仅巩固了两家公司在糖尿病科技领域的市场地位，也可能为未来更广泛的集成生态系统奠定基础。</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BBNX","symbol_name":"Beta Bionics, Inc.","start_time":0,"source_url":"","article_id":"1173059523","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173059523","pubTimestamp":1789383686,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Senseonics Holdings, Inc.今日正式宣布，已与Beta Bionics, Inc.达成一项战略合作伙伴关系。双方将携手推进连续血糖监测技术与智能胰岛素输送系统的深度融合，具体而言，Senseonics旗下创新产品Eversense 365传感器将被整合进Beta Bionics研发的Ilet仿生胰腺平台。Senseonics首席执行官在声明中表示，与Beta Bionics的合作将充分发挥各自技术优势，推动个性化糖尿病护理迈向新台阶。Beta Bionics方面亦强调，Eversense 365的长期监测能力与Ilet系统的自适应算法相结合，有望显著提升血糖控制效果，并改善患者的生活质量。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BBNX":"Beta Bionics, Inc.","SENS":"Senseonics Holdings,Inc.","BK4082":"医疗保健设备"},"translate_title":"Senseonics announced a strategic partnership with Beta Bionics to bring Eversense... ® 365 integrated into Ilet ® bionic pancreatic system","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SENS":1,"BBNX":1},"content_text":"Senseonics Holdings, Inc.（以下简称“Senseonics”）今日正式宣布，已与Beta Bionics, Inc.达成一项战略合作伙伴关系。双方将携手推进连续血糖监测技术与智能胰岛素输送系统的深度融合，具体而言，Senseonics旗下创新产品Eversense® 365传感器将被整合进Beta Bionics研发的Ilet®仿生胰腺平台。\n这一合作标志着糖尿病管理领域两大前沿技术力量的强强联合。Eversense® 365作为一款植入式连续血糖监测系统，以其长达一年的佩戴寿命和卓越的准确性著称；而Ilet®仿生胰腺则采用自动化胰岛素递送算法，能够根据实时血糖数据自主调节胰岛素输注，极大减轻患者的日常管理负担。\n通过此次整合，双方旨在为糖尿病患者打造一个更加智能化、无缝衔接的闭环管理解决方案。Senseonics首席执行官在声明中表示，与Beta Bionics的合作将充分发挥各自技术优势，推动个性化糖尿病护理迈向新台阶。Beta Bionics方面亦强调，Eversense® 365的长期监测能力与Ilet®系统的自适应算法相结合，有望显著提升血糖控制效果，并改善患者的生活质量。\n据悉，双方团队已启动技术对接与临床验证工作，后续将陆续公布更多合作细节及产品上市时间表。业内分析人士认为，此次跨界合作不仅巩固了两家公司在糖尿病科技领域的市场地位，也可能为未来更广泛的集成生态系统奠定基础。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}